NO20053837L - Farmasoytisk blanding for profylakse eller behandling av kardiovaskulaere-, kardiopulmonaere-, pulmonaere- eller nyresykdommer. - Google Patents
Farmasoytisk blanding for profylakse eller behandling av kardiovaskulaere-, kardiopulmonaere-, pulmonaere- eller nyresykdommer.Info
- Publication number
- NO20053837L NO20053837L NO20053837A NO20053837A NO20053837L NO 20053837 L NO20053837 L NO 20053837L NO 20053837 A NO20053837 A NO 20053837A NO 20053837 A NO20053837 A NO 20053837A NO 20053837 L NO20053837 L NO 20053837L
- Authority
- NO
- Norway
- Prior art keywords
- cardiopulmonary
- prophylaxis
- cardiovascular
- treatment
- hmg
- Prior art date
Links
- 238000011282 treatment Methods 0.000 title abstract 3
- 208000024172 Cardiovascular disease Diseases 0.000 title abstract 2
- 201000006306 Cor pulmonale Diseases 0.000 title abstract 2
- 230000002612 cardiopulmonary effect Effects 0.000 title abstract 2
- 230000002526 effect on cardiovascular system Effects 0.000 title abstract 2
- 208000017169 kidney disease Diseases 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 238000011321 prophylaxis Methods 0.000 title abstract 2
- 208000019693 Lung disease Diseases 0.000 title 1
- 230000002685 pulmonary effect Effects 0.000 title 1
- 108010016731 PPAR gamma Proteins 0.000 abstract 2
- 102100038825 Peroxisome proliferator-activated receptor gamma Human genes 0.000 abstract 2
- 239000002333 angiotensin II receptor antagonist Substances 0.000 abstract 2
- 229940126317 angiotensin II receptor antagonist Drugs 0.000 abstract 2
- 230000014509 gene expression Effects 0.000 abstract 2
- RMMXLENWKUUMAY-UHFFFAOYSA-N telmisartan Chemical compound CCCC1=NC2=C(C)C=C(C=3N(C4=CC=CC=C4N=3)C)C=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O RMMXLENWKUUMAY-UHFFFAOYSA-N 0.000 abstract 2
- -1 3-hydroxy-2-methylglutaryl coenzyme A Chemical compound 0.000 abstract 1
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 abstract 1
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 abstract 1
- 239000005537 C09CA07 - Telmisartan Substances 0.000 abstract 1
- 108010029697 CD40 Ligand Proteins 0.000 abstract 1
- 102100032937 CD40 ligand Human genes 0.000 abstract 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 abstract 1
- 208000001953 Hypotension Diseases 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 108010015302 Matrix metalloproteinase-9 Proteins 0.000 abstract 1
- 102100030412 Matrix metalloproteinase-9 Human genes 0.000 abstract 1
- 229940123934 Reductase inhibitor Drugs 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 230000003257 anti-anginal effect Effects 0.000 abstract 1
- 230000001088 anti-asthma Effects 0.000 abstract 1
- 230000000844 anti-bacterial effect Effects 0.000 abstract 1
- 230000003178 anti-diabetic effect Effects 0.000 abstract 1
- 230000003110 anti-inflammatory effect Effects 0.000 abstract 1
- 230000002402 anti-lipaemic effect Effects 0.000 abstract 1
- 239000000924 antiasthmatic agent Substances 0.000 abstract 1
- 239000003472 antidiabetic agent Substances 0.000 abstract 1
- 229960005370 atorvastatin Drugs 0.000 abstract 1
- 230000001966 cerebroprotective effect Effects 0.000 abstract 1
- RGJOEKWQDUBAIZ-UHFFFAOYSA-N coenzime A Natural products OC1C(OP(O)(O)=O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-UHFFFAOYSA-N 0.000 abstract 1
- 239000005516 coenzyme A Substances 0.000 abstract 1
- 229940093530 coenzyme a Drugs 0.000 abstract 1
- 239000000824 cytostatic agent Substances 0.000 abstract 1
- 230000001085 cytostatic effect Effects 0.000 abstract 1
- KDTSHFARGAKYJN-UHFFFAOYSA-N dephosphocoenzyme A Natural products OC1C(O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 KDTSHFARGAKYJN-UHFFFAOYSA-N 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000001553 hepatotropic effect Effects 0.000 abstract 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 abstract 1
- 208000021822 hypotensive Diseases 0.000 abstract 1
- 230000001077 hypotensive effect Effects 0.000 abstract 1
- 230000001506 immunosuppresive effect Effects 0.000 abstract 1
- 239000000411 inducer Substances 0.000 abstract 1
- 230000010534 mechanism of action Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000000324 neuroprotective effect Effects 0.000 abstract 1
- 230000001777 nootropic effect Effects 0.000 abstract 1
- 230000001105 regulatory effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229960005187 telmisartan Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Det beskrives en fremgangsmåte for forebyggelse eller behandling av kardiovaskulære, kardiopulmonale, pulmonale eller renale sykdommer, ved å bedre den endoteliale funksjon og oppnå en beskyttelse av organer, vev og kar ved slike indikasjoner hvor det fordres blodtrykkskontroll og en kontroll av lipidspeilet, særlig hos personer hvor diabetes mellitus type 2 er diagnostisert, eller hvor det foreligger mistanke om prediabetes, for forhindring av diabetes og prediabetes, eller for behandling av det metabolske syndrom og insulinresistens hos pasienter med normalt blodtrykk. Fremgangsmåten omfatter den felles administrering av virksomme mengder teimisartan eller en polymorf eller et salt derav, og atorvastatin. Videre beskrives egnede farmasøytiske blandinger som inneholder teimisartan eller en polymorf eller et salt derav, og atorvastatin som kombinasjonspreparat for samtidig, adskilt eller suksessiv anvendelse ved forebyggelsen eller behandlingen av disse sykdommene.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10301371A DE10301371A1 (de) | 2003-01-16 | 2003-01-16 | Pharmazeutische Kombination zur Prophylaxe oder Therapie von kardiovaskulären, kardiopulmonalen, pulmonalen oder renalen Krankheiten |
| DE10335027A DE10335027A1 (de) | 2003-07-31 | 2003-07-31 | Verwendung von Angiotensin II Rezeptor Antagonisten |
| PCT/EP2004/000174 WO2004062557A2 (de) | 2003-01-16 | 2004-01-14 | Pharmazeutische kombination aus telmisartan und atorvastatinph zur prophylaxe oder therapie von kardiovaskulären, kardiopulmonalen, pulmonalen oder renalen krankheiten |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20053837L true NO20053837L (no) | 2005-08-15 |
Family
ID=32714791
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20053837A NO20053837L (no) | 2003-01-16 | 2005-08-15 | Farmasoytisk blanding for profylakse eller behandling av kardiovaskulaere-, kardiopulmonaere-, pulmonaere- eller nyresykdommer. |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US20040259925A1 (no) |
| EP (1) | EP1587479B1 (no) |
| JP (1) | JP2006515614A (no) |
| KR (1) | KR20050092121A (no) |
| CN (1) | CN1738617A (no) |
| AT (1) | ATE536871T1 (no) |
| AU (1) | AU2004204352B2 (no) |
| BR (1) | BRPI0406455A (no) |
| CA (1) | CA2513277A1 (no) |
| DE (1) | DE10301371A1 (no) |
| EA (1) | EA009874B1 (no) |
| EC (1) | ECSP055915A (no) |
| HR (1) | HRP20050654A2 (no) |
| MX (1) | MXPA05007103A (no) |
| NO (1) | NO20053837L (no) |
| NZ (1) | NZ541747A (no) |
| PL (1) | PL378225A1 (no) |
| RS (1) | RS20050537A (no) |
| UA (1) | UA84282C2 (no) |
| WO (1) | WO2004062557A2 (no) |
| ZA (1) | ZA200503542B (no) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7232828B2 (en) * | 2002-08-10 | 2007-06-19 | Bethesda Pharmaceuticals, Inc. | PPAR Ligands that do not cause fluid retention, edema or congestive heart failure |
| DE10335027A1 (de) * | 2003-07-31 | 2005-02-17 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verwendung von Angiotensin II Rezeptor Antagonisten |
| DE10319450A1 (de) * | 2003-04-30 | 2004-11-18 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Pharmazeutische Formulierung des Telmisartan Natriumsalzes |
| US9029363B2 (en) * | 2003-04-30 | 2015-05-12 | Boehringer Ingelheim International Gmbh | Telmisartan sodium salt pharmaceutical formulation |
| CN1812983A (zh) | 2003-05-30 | 2006-08-02 | 兰贝克赛实验室有限公司 | 取代的吡咯衍生物及其作为hmg－co抑制剂的用途 |
| RS53141B (sr) * | 2004-11-05 | 2014-06-30 | Boehringer Ingelheim International Gmbh | Dvoslojna tableta koja sadrži telmisartan i amlodipin |
| WO2006050923A1 (en) * | 2004-11-11 | 2006-05-18 | Lek Pharmaceuticals D.D. | Polymorph form of irbesartan |
| WO2007051007A2 (en) * | 2005-10-28 | 2007-05-03 | Novartis Ag | Combination of antihypertensives with cholesterol-lowering agent |
| SG166829A1 (en) * | 2005-11-08 | 2010-12-29 | Ranbaxy Lab Ltd | Process for (3r, 5r)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4- [(4-hydroxy methyl phenyl amino) carbonyl]-pyrrol-1-yl]-3, 5-dihydroxy-heptanoic acid hemi calcium salt |
| WO2008010008A2 (en) * | 2006-07-17 | 2008-01-24 | Wockhardt Limited | Cardiovascular combinations using rennin-angiotensin inhibitors |
| US8445437B2 (en) * | 2006-07-27 | 2013-05-21 | The Brigham And Women's Hospital, Inc. | Treatment and prevention of cardiovascular disease using mast cell stabilizers |
| US8642083B2 (en) * | 2006-10-30 | 2014-02-04 | Hanall Biopharma Co., Ltd. | Controlled release complex composition comprising angiotensin-II-receptor blockers and HMG-CoA reductase inhibitors |
| JP5460600B2 (ja) | 2007-09-28 | 2014-04-02 | ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド | 肥満症治療における肥満細胞安定化薬 |
| KR100893652B1 (ko) | 2008-11-10 | 2009-04-17 | 주식회사종근당 | 신규한 텔미사르탄 아연염 및 그의 제조방법 |
| CZ2008740A3 (cs) * | 2008-11-24 | 2010-01-06 | Zentiva, A.S. | Pevná farmaceutická kompozice s úcinnými látkami atorvastatinem a telmisartanem |
| CN102028682A (zh) * | 2010-12-16 | 2011-04-27 | 施慧达药业集团(吉林)有限公司 | 一种包含替米沙坦和阿托伐他汀的复方药物制剂 |
| HRP20170263T2 (hr) * | 2011-12-09 | 2018-12-28 | Ims Medical D.O.O. | LIJEČENJE ARTERIJSKE STJENKE KOMBINACIJOM RAAS INHIBITORA I HMG-CoA REDUKTAZE |
| WO2019018849A1 (en) * | 2017-07-21 | 2019-01-24 | Kieu Hoang | STATINES (ATORVASTATIN) THAT CAN REDUCE GLYCEMIA LEVEL IN DIABETICS |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6107323A (en) * | 1996-04-05 | 2000-08-22 | Takeda Chemical Industries, Ltd. | Pharmaceutical composition |
| US20010006656A1 (en) * | 1999-02-17 | 2001-07-05 | University Of Washington | Methods and compositions for inhibiting inflammation associated with pulmonary disease |
| HUP0203326A3 (en) * | 1999-08-30 | 2003-04-28 | Sanofi Aventis Deutschland | Use of inhibitors of the renin-angiotensin system in the prevention of cardiovascular events |
| CA2405793A1 (en) * | 2000-04-12 | 2001-10-18 | Novartis Ag | Combination of organic compounds |
| US20020013334A1 (en) * | 2000-06-15 | 2002-01-31 | Robl Jeffrey A. | HMG-CoA reductase inhibitors and method |
| GB0020691D0 (en) * | 2000-08-22 | 2000-10-11 | Boehringer Ingelheim Pharma | Pharmaceutical combination |
| AU2001284413A1 (en) * | 2000-08-30 | 2002-03-13 | Sankyo Company Limited | Medicinal compositions for preventing or treating heart failure |
| US7232828B2 (en) * | 2002-08-10 | 2007-06-19 | Bethesda Pharmaceuticals, Inc. | PPAR Ligands that do not cause fluid retention, edema or congestive heart failure |
| JP4585198B2 (ja) * | 2002-12-27 | 2010-11-24 | 武田薬品工業株式会社 | 体重増加抑制剤 |
-
2003
- 2003-01-16 DE DE10301371A patent/DE10301371A1/de not_active Withdrawn
-
2004
- 2004-01-14 PL PL378225A patent/PL378225A1/pl not_active Application Discontinuation
- 2004-01-14 MX MXPA05007103A patent/MXPA05007103A/es active IP Right Grant
- 2004-01-14 US US10/757,295 patent/US20040259925A1/en not_active Abandoned
- 2004-01-14 UA UAA200507993A patent/UA84282C2/ru unknown
- 2004-01-14 EA EA200501058A patent/EA009874B1/ru not_active IP Right Cessation
- 2004-01-14 AT AT04701904T patent/ATE536871T1/de active
- 2004-01-14 CA CA002513277A patent/CA2513277A1/en not_active Abandoned
- 2004-01-14 RS YUP-2005/0537A patent/RS20050537A/sr unknown
- 2004-01-14 BR BR0406455-0A patent/BRPI0406455A/pt not_active IP Right Cessation
- 2004-01-14 AU AU2004204352A patent/AU2004204352B2/en not_active Ceased
- 2004-01-14 JP JP2006500557A patent/JP2006515614A/ja active Pending
- 2004-01-14 HR HR20050654A patent/HRP20050654A2/hr not_active Application Discontinuation
- 2004-01-14 NZ NZ541747A patent/NZ541747A/en not_active IP Right Cessation
- 2004-01-14 KR KR1020057013217A patent/KR20050092121A/ko not_active Ceased
- 2004-01-14 EP EP04701904A patent/EP1587479B1/de not_active Expired - Lifetime
- 2004-01-14 WO PCT/EP2004/000174 patent/WO2004062557A2/de not_active Ceased
- 2004-01-14 CN CNA2004800024072A patent/CN1738617A/zh active Pending
-
2005
- 2005-05-04 ZA ZA200503542A patent/ZA200503542B/en unknown
- 2005-07-12 EC EC2005005915A patent/ECSP055915A/es unknown
- 2005-08-15 NO NO20053837A patent/NO20053837L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| KR20050092121A (ko) | 2005-09-20 |
| ECSP055915A (es) | 2006-03-01 |
| ZA200503542B (en) | 2006-07-26 |
| CN1738617A (zh) | 2006-02-22 |
| WO2004062557A3 (de) | 2004-09-16 |
| PL378225A1 (pl) | 2006-03-20 |
| DE10301371A1 (de) | 2004-08-05 |
| AU2004204352B2 (en) | 2009-07-30 |
| EP1587479B1 (de) | 2011-12-14 |
| BRPI0406455A (pt) | 2005-12-06 |
| ATE536871T1 (de) | 2011-12-15 |
| RS20050537A (sr) | 2007-09-21 |
| EA009874B1 (ru) | 2008-04-28 |
| EA200501058A1 (ru) | 2006-02-24 |
| HRP20050654A2 (en) | 2006-05-31 |
| UA84282C2 (ru) | 2008-10-10 |
| AU2004204352A1 (en) | 2004-07-29 |
| CA2513277A1 (en) | 2004-07-29 |
| US20040259925A1 (en) | 2004-12-23 |
| MXPA05007103A (es) | 2005-08-26 |
| EP1587479A2 (de) | 2005-10-26 |
| NZ541747A (en) | 2009-09-25 |
| WO2004062557A2 (de) | 2004-07-29 |
| JP2006515614A (ja) | 2006-06-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL378225A1 (pl) | Kompozycja farmaceutyczna do zapobiegania lub leczenia chorób sercowo-naczyniowych, sercowo-płucnych, płucnych lub nerek | |
| WO2005082863A3 (en) | 1,4 diaryl-dihydropyrimidin-2 ones and their use as a human neutrophil elastase inhibitors | |
| NO20161634A1 (no) | 3-Z-[1-(4-(N-((4-metyl-piperazin-1-yl)-metylkarbonyl)-N-metyl-amino)-anilino)-1-fenyl-metylen]-6-metoksykarbonyl-2-indolinon, tautomerene, diastereomerene, enantiomerene, blandinger derav og saltene derav, og i kombinasjon med en ytterligere farmakologisk aktiv substans, for anvendelse i forebygging eller behandling av fibrose ved revmatoid artritt | |
| NO20051726L (no) | Pyrimidinonderivaer som terapeutiske midler ovenfor akutte og kroniske inflammasjons-, iskemiske og remodeleringsprosesser | |
| PL376213A1 (en) | Pharmaceutical combination for the prophylaxis or treatment of cardiovascular, cardiopulmonary, pulmonary or renal diseases | |
| NO20024772D0 (no) | Percyquinnin, fremgangsmåte for dets fremstilling og dets anvendelse som et legemiddel | |
| CY1108932T1 (el) | Ενωσεις 4-(ετεροκυκλυλ)-βενζολοσουλφοξιμινης για την θεραπευτικη αγωγη φλεγμονωδων ασθενειων | |
| NO20032861L (no) | Heteroarylurea nevropeptid Y Y5-reseptorantagonister | |
| NO20055305D0 (no) | Pyrrolopyridin-2-karboksylsyreamid-inhibitorer av glykogenfosforylase | |
| JP2007277267A5 (no) | ||
| ATE368647T1 (de) | Pharmazeutische zusammensetzung und ihre verwendung als inhibitoren von der dipeptidyl peptidase iv (dpp-iv) | |
| NO20034986D0 (no) | Furan og tiofenderivater som aktiverer human peroksisom proliferator aktiverte reseptorer | |
| NO20011721L (no) | N-aralkylaminotetraliner som ligander for neuropeptid Y Y5- reseptoren | |
| ATE411288T1 (de) | Aryl-, aryloxy- und alkyloxysubstituierte 1h- indol-3-yl-glyoxylsäurederivateals inhibitoren des plasminogenaktivatorinhibitors-1 (pai-1) | |
| ATE384058T1 (de) | Thiazolderivate | |
| NO20033491L (no) | Heterocykliske inhibitorer samt anvendelse derav for fremstilling av medikamenter til hemming av ERK2, Aurora-2, GSK-3, CDK-2 eller Lck-aktivitet | |
| ATE382043T1 (de) | Sulfonamid-derivate als ppar-modulatoren | |
| AU2003287914A1 (en) | Piperidine and pyrrolidine derivatives as antagonists of histamine h3 receptor | |
| AR038305A1 (es) | Composicion farmaceutica dispersable oralmente de perindopril | |
| ATE373636T1 (de) | Amidderivate als inhibitoren der enzymatischen aktivität von renin | |
| WO2000048447A3 (en) | Composition for treatment of external secretion disorders except hypolacrimation | |
| NO20044673L (no) | Farmasoytisk kombinasjon | |
| SE0201939D0 (sv) | New combination | |
| EA200100876A2 (ru) | Фармацевтическая композиция для предупреждения или лечения заболевания, связанного с избыточным продуцированием il-12 | |
| MA28399B1 (fr) | Modulateurs selectifs de recepteurs actives par les proliferateurs de peroxysome |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |